MAGEA3 and non-small cell lung carcinoma: A gene signature that aided in clinical benefit to MAGE-A3 was not observed because disease free survival (DFS) did not escalate on NSCLC in either the overall popula-tion or in NSCLC patients who did not receive ACT after treatment.